ArticleFrontiers in medicine2025
Optimal dosing regimen of ondansetron oral soluble pellicles for preventing postoperative nausea and vomiting after primary total joint arthroplasty: a randomized controlled clinical trial.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The widespread use of high-dose antifibrinolytic agents (tranexamic acid) and opioids in total joint arthroplasty (TJA) has highlighted a critical concern: postoperative nausea and vomiting (PONV). Ondansetron, recognized as a cornerstone medication for PONV prevention in clinical guidelines, offers an innovative solution through its oral soluble pellicle (OSP) formulation. We conducted this study to investigate the optimal dosing regimen of ondansetron OSPs for preventing PONV following primary TJA. Methods: This randomized, controlled, double-masked clinical trial allocated 198 patients to three intervention groups: (1) Preop 16 mg group: Two ondansetron OSPs (16 mg) administered orally 1 h before induction, followed by placebo films at 6 and 12 h postoperatively; (2) 16 + 8 mg group: Two ondansetron OSPs (16 mg) administered preoperatively, followed by one ondansetron OSP (8 mg) at 6 h and one placebo film at 12 h postoperatively; (3) 8 + 8 + 8 mg group: One ondansetron OSP (8 mg) and one placebo film administered preoperatively, followed by one ondansetron OSP (8 mg) at both 6 and 12 h postoperatively. The primary outcome assessed the incidence and severity of PONV within 48 h after TJA. Secondary outcomes included the utilization frequency of rescue metoclopramide and tramadol, along with adverse drug reactions (ADRs). Results: The primary outcomes demonstrated that both the Preop 16 mg and 16 + 8 mg groups achieved significantly lower incidences of postoperative nausea compared to the 8 + 8 + 8 mg group, although no statistically significant differences were observed among the three groups in nausea severity (visual analog scale (VAS) scores) or postoperative vomiting frequency. The secondary outcomes showed significantly reduced metoclopramide utilization in the 16 + 8 mg group versus the 8 + 8 + 8 mg group, with a non-significant trend in the Preop 16 mg group, while tramadol usage and ADR rates showed no significant intergroup differences. Conclusion: Compared to the 8 + 8 + 8 mg regimen, both the Preop 16 mg and 16 + 8 mg dosing strategies demonstrated superior efficacy. For high-risk patients, the 16 + 8 mg regimen may represent the optimal therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.